Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Dextrum Laboratories Inc.
WARNING LETTER
•Dextrum Laboratories Inc.•July 18, 2023

Dextrum Laboratories Inc. – FDA Warning Letter, Jul 18, 2023

Record Details

The FDA issued a Warning Letter to Dextrum Laboratories Inc. following an inspection from July 10-18, 2023, identifying significant Current Good Manufacturing Practice (CGMP) violations for finished pharmaceuticals, rendering their drug products adulterated.

Key violations include: 1. **Failure to conduct identity testing for drug product components (21 CFR 211.84(d)(1)):** The firm, a contract manufacturer of OTC cough and cold products, did not adequately test each component lot, including active pharmaceutical ingredients like dextromethorphan, and high-risk components like glycerin, for identity and hazardous impurities such as diethylene glycol (DEG) or ethylene glycol (EG). Their response, proposing periodic third-party testing, was deemed inadequate as it lacked commitment to testing each lot and a retrospective review of previously used materials. 2. **Failure to conduct microbiological testing of components with potential for objectionable contamination (21 CFR 211.84(d)(6)):** The firm failed to adequately monitor the microbiological quality of their (b)(4) water used in manufacturing, only testing on a (b)(4) basis, despite identifying dead legs in their water system. 3. **Failure to establish adequate written procedures for production and process control (21 CFR 211.100(a)):** The firm did not adequately validate production and process controls for their OTC drug products,

Company
Dextrum Laboratories Inc.
Inspection date
July 18, 2023
Product type
Drugs
Office
Division of Pharmaceutical Quality Operations II
Person
  • Ronda R. Lloyd-Jones (Director of Compliance Branch)
View Company Profile

ID · 70960935-81af-49dc-99ae-c3a2ca512f89

Violation Codes7
21 CFR 21021 CFR 21121 CFR 211.84(d)(1)21 CFR 211.84(d)(6)21 CFR 211.100(a)FD&C Act 501(a)(2)(B)21 U.S.C. 351(a)(2)(B)

Full citation text and observation details available on the Dashboard.

Other documents for Dextrum Laboratories Inc.
  • 483 - 2024-08-29August 29, 2024
  • 483 - 2023-07-18July 18, 2023
  • 483 - 2022-12-16December 16, 2022

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Dextrum Laboratories Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.